Table 3 Multivariate analysis of predictors of an adverse outcome.
All patients | Conservative group | AVR | ||||
---|---|---|---|---|---|---|
Wald | p Value | Wald | p Value | Wald | p Value | |
NT‐proBNP ⩾640 pg/ml | 4.45* | 0.035* | 5.24* | 0.022* | 0.09 | 0.766 |
Rhythm | 3.83* | 0.050* | 0.82 | 0.364 | 6.37* | 0.012* |
Age | 1.08 | 0.299 | 1.99 | 0.158 | 2.48 | 0.116 |
Mean pressure gradient | 0.96 | 0.326 | 0.00 | 0.949 | 0.11 | 0.741 |
Sex | 0.39 | 0.533 | 0.19 | 0.659 | 0.16 | 0.685 |
NYHA class III or IV | 0.39 | 0.533 | 0.05 | 0.823 | 0.89 | 0.345 |
Ejection fraction | 0.28 | 0.596 | 7.27* | 0.007* | 0.00 | 0.964 |
Coronary artery disease | 0.15 | 0.697 | 1.91 | 0.167 | 0.45 | 0.501 |
*Significant predictor.
Multivariate Cox regression analysis for predictors of an adverse outcome (cardiac death and rehospitalisation for decompensated heart failure) for the entire study group, conservatively treated patients and patients who underwent valve surgery.
AVR, aortic valve replacement; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association.